MetaCap

Alumis Inc. (ALMS)

NASDAQ: ALMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.96-0.37 (-8.55%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALMS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$514.09M
EPS (TTM)
-$3.53
52-week range
3.94 – 31.35
Day range
3.94 – 4.36
Volume / Avg
1.79M / 2.87M
Beta
—

52-week range

$3.94$31.35

ALMS stock today

On Nov 20, ALMS ended the session at $3.96, shedding $0.37 (8.55%), versus the S&P 500's 3.70% decline. Shares are 87.4% below their 52-week high of $31.35, set on Jul 8, 2026 and 0.6% above the 52-week low of $3.94, near the bottom of the past year's range. ALMS is down 59.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 45.8%.

Alumis has posted a net loss over the last twelve months (EPS of -$3.53), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Alumis

Company profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Martin Babler Ph.D.
Headquarters
South San Francisco, CA
Employees
251
IPO year
2024
Website
alumis.com

Financial highlights

Full financials

In fiscal 2025, Alumis generated $24.1 million in revenue. Alumis reported a net loss of $243.3 million, compared with a loss of $294.2 million a year earlier. Operating margin was -1886.9%.

Alumis annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue$24.05M——
Growth———
Net income$-243.32M$-294.23M$-154.99M
EPS (diluted)$-2.86$-10.38$-72.08

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$25.38+540.91%

  • Strong buy 1
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $46.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.73 vs $-0.73

ALMS news

All ALMS news

Alumis peers

Health Care sector
ALMS peer companies
CompanyPrice% ChgMarket capCompare
ZVRAZevra Therapeutics Inc.8.76-3.42%$521.26Mvs ALMS
WVEWave Life Sciences Inc.2.56-5.88%$504.91Mvs ALMS
CLYMClimb Bio Inc.9.19-0.97%$539.80Mvs ALMS
HELPHelus Pharma Inc.6.11-9.88%$487.68Mvs ALMS
CBIOCrescent Biopharma Inc.13.00+0.70%$543.21Mvs ALMS
AVBPArriVent BioPharma Inc.10.52-6.57%$544.13Mvs ALMS
ACRSAclaris Therapeutics Inc.3.44-1.71%$545.63Mvs ALMS
ANLAdlai Nortye Group Ltd. ADR8.55-5.63%$550.60Mvs ALMS

Indexes, lists and sector

Alumis stock FAQ

What is Alumis's stock price today?

ALMS last traded at $3.96 as of Nov 20, 4:00 PM EST, down 8.55% on the day. Prices are delayed at least 15 minutes.

Who is Alumis's CEO?

Mr. Martin Babler Ph.D. is the chief executive officer of Alumis Inc., which has about 251 employees.

What is the ALMS 52-week high?

The 52-week high for ALMS is $31.35 and the 52-week low is $3.94. The stock is currently 87.4% below its high.

Compare ALMS